Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hpv electroporation DNA vaccine http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0060507 Read this article it validates the intrest from big pharma read the company's affiliated with this research
i was wondering if anyone has spoke to Bernie this week, i was going to call him but figured he's heard enough from me the last few months
.02 is good anything below is really good and take that right away
ya these swings are for sure the play for today
damn its runs hard then then momentum slows would you guys suggest playing the swings or being patient
what Resistance do we need to break to really run
thats what happened it got pumped and dumped so i bought after the dump now here we are rising off news not some bs website
These results do not include the second part of study which is
Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults
Novel Vaccine Strategies Tuesday 2:30-4 pm March 5th 2013..check it out Study of PENNVAX
Here is what was presented March 5th at the CROI conference 2013.. don't worry if you weren't aware we attended no pr was released about it
Paper #390
Potent Cellular Immune Responses Induced after Therapeutic Immunization of HIV+ Patients with PENNVAX-B DNA Vaccine Delivered by Electroporation
Lorenzo Ramirez*1, T Arango1, D Shah2, M Morrow2, J Lee2, M Naji1, K Maffei3, M Bagarazzi2, P Tebas3, and J Boyer1
1Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US; 2Inovio Pharmaceuticals, Blue Bell, PA, US; and 3Univ of Pennsylvania, Philadelphia, US
Background: The goal of eradicating the HIV reservoir has renewed interest in immunotherapeutic approaches to boost T cell responses against HIV+ cells. However, individuals chronically infected with HIV respond poorly to T cell vaccines. We evaluated the use of PENNVAX-B vaccine (a gag, pol, and env combination DNA vaccine) delivered by in vivo electroporation (EP) that has proven immunogenic in HIV– individuals (HVTN 080).
Methods: We conducted a phase 1 study in well controlled, ART treated, HIV+ individuals (HIV RNA <75 copies/mL, current CD4 >400/µL, and nadir CD4 cells >200 cells/µL). Subjects received 4 doses (at day 0, weeks 4, 8, and 16) of 3 mg PENNVAX-B (consisting of consensus sequence HIV gag, pol, and env immunogens) intramuscularly followed by EP. Standard IFN-? ELISpot assays were performed. Positive responses were determined using a one-way ANOVA followed by Dunnett’s test, comparing each time-point to baseline. We measured the potential of cells to lyse HIV-1+ cells by measuring CD8+CD107a+ Perforin+ Granzyme B+ responses, by standard flow cytometry. Subjects were considered responders to the vaccine if responses were 50% greater than baseline. Also, the subjects’ pre-vaccination cytokine profiles were examined using a 30 cytokine Luminex plasma assay. We compared baseline cytokine profiles of the subjects who responded via ELISpot or Flow assays to those who did not respond.
Results: 12 subjects were included. 92% were male and 58% black. The vaccine was safe and well tolerated. 10 of the 12 subjects (83%) showed significant vaccine-specific T cell responses in the form of IFN-? ELISpot to at least 1/3 vaccine antigens (gag, pol, or env) throughout the immunizations. ELISpot responses were primarily mediated by CD8+ T cells. 9/11 subjects tested showed a positive CD8+CD107a+ Perforin+ Granzyme B+ response. HIV-1+ individuals, despite having well-controlled viral replication showed significantly different cytokine profiles compared to healthy controls. Importantly, baseline IL-12 p70, and MCP-1 levels were directly associated with response to the HIV-1 therapeutic vaccine.
Conclusions: PENNVAX-B induced HIV-specific CTL responses in well-controlled HIV+ individuals. The pre-vaccination cytokine environment may provide the necessary signals for T cells to respond to therapeutic vaccination, suggesting that the cytokines examined could serve as potential adjuvants in a therapeutic vaccine strategy.
.10 i know it could hit ten its been there more then once idk what it would take us to move like that though any benchmarks or catalyst you have in mind
I got in at .02 selling for anything less then 4 isnt worth it for me. How long it will take to get there i have no idea but ill be patiently waiting until then
how is L2 looking ?
no problem
kyle.ramer • Feb 4, 2013 12:36 PM Flag
22users liked this postsusers disliked this posts36Reply
data due to be released FIRST HALF OF 2013
1)ChronVac-C® hepatitis C vaccine-Interim results of phase II (1Q 2013)
2)Seasonal Flu (H5N1 + H1N1)-Report interim phase I clinical data (1H 2013)
3)PENNVAX®-B HIV Vaccine-Final HIV-001 results expected in 1H 2013
4)HIV type-1 clades A and C-Initiate phase I clinical trial 1H 2013
5)Prostate cancer-Initiate phase I clinical trial (1H 2013)
http://www.retroconference.org/2013b/PDFs/879.pdf check out now get back to me
yep no point to sell these lows ill wait for news
i hear you, no i don't think there is complete transparency to answer you question, as far as suppressing pps until option is exercised how could that happen unless your speculating on investor sentient
if you read the filing it gives detailed explanation what the shares would be used for..you did read it right?
im in and do belive stock could run..but what reasons do u have to be so bullish on this the next few days
some pr would be nice
are they trying to walk this down ? this stock very well could explode i just hate the fact mm's can f with the a/b
any idea what pps this will open at due to this trade showing a price increase 146%